semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 60.0-85.0,  Male Osteoporosis DXA BMD T-score < or = -2.0 at either lumbar spine (LS), femoral neck (FN) or total hip (TH) sites; or DXA BMD T-score < or = -1.5 with at least one additional important clinical risk factor for osteoporotic fracture [e.g., fragility fracture after age 50 years; parental history of hip fracture; history of hypogonadism, prior glucocorticoid therapy (>3 months prior), current smoking, prevalent vertebral fracture(s), or prior hyperthyroidism on stable treatment] At least 2 LS vertebral levels with reliable BMD values (i.e., at least 2 without compression or hardware)  Metabolic bone disease other than osteoporosis (e.g., Paget's disease, hyperparathyroidism) Any osteoporosis drug therapy within 12 months; any prior course of TPTD for > or = 3 months; any history of IV bisphosphonate therapy; oral bisphosphonate therapy exceeding 3 months in past 2 years; oral bisphosphonate treatment exceeding 2 years ever; or use of denosumab (within the past 3 years or > 3 or = injections ever) Oral glucocorticoid use (> or = 5 mg prednisone) taken within 3 months prior to enrollment Hypercalcemia (albumin-corrected serum [Ca] >10.2 mg/dL), hypocalcemia (albumin-corrected serum [Ca] <8.8 mg/dL), elevated intact PTH level, or hypercalciuria (urinary Ca >300 mg/24 hours) at screening OH vitamin D levels <20 ng/ml or >80 ng/ml at screening Estimated glomerular filtration rate < 30 ml/min (chronic kidney disease (CKD) stage 4 or 5) Cancer within past 5 years except for non-melanomatous skin cancers History of skeletal radiation, prior history of osteosarcoma or bone metastases Substance abuse (>3 drinks/day), liver disease or impaired liver function (abnormal liver function tests defined as greater than 3 times the upper limit of normal), known cirrhosis, malabsorption Poorly controlled diabetes (A1c >9.0%) or current thiazolidinedione therapy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ckd-Mbd CKD Patients with GFR <60 non-dialysis age<18  HTN not signing consent active coronary disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Phosphorus and Calcium Disorders Chronic Kidney Disease Mineral and Bone Disorder Chronic Kidney Diseases Men or women, ages 30-75 years old, any race or ethnicity Moderate chronic kidney disease Female subjects must be postmenopausal (>12 months since last menstrual period), surgically sterile, or confirmed not pregnant by pregnancy test Must be on stable doses of medications (except those noted in  ) for at least 4 weeks prior to the study Willing to discontinue nutritional supplements (e.g. vitamin D, calcium, multivitamin/minerals, or others) upon enrollment until completion of the study Adequate vitamin D status defined as serum 25D > 20 ng/mL Plans to initiate dialysis within 6 months Hypercalcemia defined as serum calcium >10.5 mg/dL within past 3 months Hyperkalemia defined as serum potassium >5.5 mg/dL within past 3 months Hyperphosphatemia defined as serum phosphate >5.5 mg/dL within past 3 months Intestinal disease that alters absorption or normal intestinal function including celiac disease, small bowel resection, or bariatric surgery Serious, uncontrolled underlying systemic disease including diabetes, lupus, hypertension Pregnant or breastfeeding
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Postoperative Nausea and Vomiting Individuals who volunteered to participate in the study Individuals who have the ability to make decisions Thyroidectomy operation Laparoscopic cholecystectomy (Lap. Chol.) operation Individuals who score 2/5 or more out of the Koivuranta PONV risk factors*  Patients with diabetes Nothing by mouth patients (for other reasons than surgery) Gastrointestinal system surgery patients Individuals with pollen allergy Koivuranta PONV risk factors: Female gender, Non-smoking individuals History of PONV History of motion sickness Anesthesia duration
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 26.0-75.0,  Vitamin Deficiency Healthy volunteers whose circulating serum vitamin A1, E, B1,B2,B6,B12,C,D, Calcium, Iron, IGF-1 and FT-3 are within normal limits. A1; 48-85 ug/dl, E; 5.3-17.5 mg/L, B1; 66.5-200 nmo/L, B2; 137-370 ug/L, B6; 2-32.8 ug/L, B12; 211-946 pg/mL, C; 0.2-2.0 mg/dL, D; 30-100 ng/mL, Calcium; 8.7-10.2 mg/dL, Iron; 27-159 ug/dL, IGF-1; 67-205 ng/mL, FT-3; 2-4.4 pg/mL  Volunteers whose circulating serum vitamin A1, E, B1,B2,B6,B12,C,D, Calcium, Iron, IGF and FT-3 are outside normal limits. A1; 48-85 ug/dl, E; 5.3-17.5 mg/L, B1; 66.5-200 nmo/L, B2; 137-370 ug/L, B6; 2-32.8 ug/L, B12; 211-946 pg/mL, C; 0.2-2.0 mg/dL, D; 30-100 ng/mL, Calcium; 8.7-10.2 mg/dL, Iron; 27-159 ug/dL, IGF-1; 67-205 ng/mL, FT-3; 2-4.4 pg/mL -
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 55.0-110.0,  Aging Problems Frailty Fall Injury Accidental Fall Fear of Falling years of age Understanding oral and written communication in Swedish  Cannot sit up without support Not being able to hold up neck when laying on the floor or rolling backwards Aortic aneurysm Angina pectoris Cataract operation within the last 6 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Peripheral Nerve Injury at Forearm Level (Diagnosis) Willing to sign the inform consent Sufficiently communicate in the Chinese language Be able to follow instructions Newly median, ulnar, or radial nerve repair at forearm level in recent 3 weeks  Pregnant or breast-feeding woman Central nervous disease A history of nerve entrapment syndrome in recent 1 year Patients with a history of latent neuropathy, such as diabetes, dialysis, and tumor Unable to communicate or comprehend the questionnaires
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ataxia having a predominant phenotype of pure or complex cerebellar ataxia of probable genetic origin (after of acquired, inflammatory, tumoral, infectious or toxic forms) - having started before the age of 50 evoking a modality of recessive transmission (sporadic cases, brothers or sister affected, consanguinity of the parents) in which dominant genetic forms due to CAG expansion (SCA1, SCA2, SCA3, SCA6, SCA7) and pre-mutation of the FMR1 gene (if onset after age 45)  objecting to the computer processing of the data contained in the medical file
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Copd Obese Obesity, Abdominal COPD diagnosis, informed consent for voluntary participation in the study  patient participation in any interventional study COPD exacerbation concomitant lung diseases, such as confirmed or suspected malignant lung disease or other respiratory disease, such as interstitial pulmonary fibrosis, tuberculosis, sarcoidosis, bronchial asthma, bronchiectasis concomitant diseases of other organs and systems, such as acute cardiovascular diseases, chronic kidney diseases and liver failure
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Glenohumeral Osteoarthritis All Danish citizens with glenohumeral osteoarthritis indicating a total shoulder arthroplasty referred to the orthopedic department at Copenhagen University Hospital in Gentofte  below 18 years of age cognitive or linguistic impairment insufficient function of the rotator cuff poor bone quality ASA group 4-5
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Depression Anxiety female Tajik citizen between 18 and 45 years old score >16 on the HAM-D no current or past substance use willing to participate in the intervention and research procedures able to give written informed consent  women who are older or younger than 18 years women who do not score >16 on the HAM-D
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Informed consent as documented by signature Age 18 years or older Seeking care for new onset of non-specific or specific LBP (pain duration of less than 12 weeks LBP prior to the baseline visit) The GP plans to prescribe a non-opioid pain medication for pain control  Presence of red flags (serious neurological deficit requiring surgery, infection, vertebral fracture) Active malignancy and / or history of a (previous) hematologic disorder (anemia (hemoglobin < 10.0 g/L), neutropenia or agranulocytosis, thrombocytopenia) Known contraindications against the study medications: heart failure (NYHA III-IV), liver failure (liver cirrhosis, ascites), renal insufficiency (estimated glomerular filtration rate (eGFR) < 60 ml/min/1,73 m2) or previous acute kidney injury (AKI stage 2 according to the KDIGO definition), previous gastrointestinal ulcer, inflammatory bowel disease Immune deficiency or under immunosuppressant treatment Current use of opioids Known intolerance to the study medication (i.e. previous acute allergic reaction to the study medication) Patients unable or unwilling to follow instructions or do not speak and are unable to read / understand German Patients unable to provide informed consent themselves Known or suspected non-compliance, drug or alcohol abuse Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Musculoskeletal Pain Acute musculoskeletal pain: Any pain attributable to muscles, bones, joints, tendons, ligaments or supporting structures, as determined by the clinical team, of 10 days duration or less. Prior to the onset of acute pain, patients cannot have experienced pain in the same body region during the prior six months Pain has to be described as moderate or severe, when the patient is asked if the pain is mild, moderate or severe in intensity  Use of an non-steroidal anti-inflammatory drug within the previous six hours Use of acetaminophen within the previous six hours Use of an opioid within the previous ten days Chronic pain, defined as any pain on >50% of days for at least 3 months prior to onset of acute pain Gout
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Child Malnutrition Breast Feeding Nutrition Married adult woman (all married women are considered adults in Afghanistan, regardless of age) Has a child between 6 and 23 months of age. For women with more than one living child between ages 6 and 23 months, questions will be asked regarding dietary experiences for the elder of the two. For twins or multiple order siblings, the eldest will be selected based on birth order Resident in the household  No specific
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Retinopathy Macular Degeneration Glaucoma Retinitis Pigmentosa Vision Disorders Acute Coronary Syndrome Implantable Defibrillator User Congestive Heart Failure Hypertrophic Obstructive Cardiomyopathy Orthostatic Hypotension Syncope Presyncope Narcolepsy Dementia Multiple Sclerosis Parkinson Disease Brain Injuries Spinal Cord Injuries Stroke Vertigo Dizziness Seizures Substance Use Insulin Dependent Diabetes Mellitus Arthritis Foot--Abnormalities Chronic Obstructive Pulmonary Disease Obstructive Sleep Apnea End Stage Renal Disease Sleep Apnea Insomnia Restless Legs Syndrome for drivers years or older Fluent in English At least one medical condition linked in driving cessation Drive at least one time per week Have a study partner* (*drivers interested in participating in the study without a study partner will be placed on a wait list; they may be contacted as a later date for enrollment once 200 driver-study partner dyads have been enrolled across all sites) minute MoCA score greater or equal to 21  for drivers In legal custody or institutionalized Significant cognitive impairment as measured by 5-minute Montreal Cognitive Assessment (MoCA) Since the last time they had their license renewed, has had at least one major change to health, vision, or hearing that has seriously impaired driving (based on potential participant self-report) Feels the Department of Motor Vehicles would have serious concerns about their driving (based on potential participant self-report) for study partners years or older Fluent in English Identified by Driver participant to contact for potential participation, i.e., part of a driver-study partner dyad minute MoCA score greater or equal to 21 for study partners
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 3.0-5.0,  Pit and Fissure Caries Glass Ionomer Cements Tooth, Deciduous Child Generally healthy children aged between 3-5 years with no remarkable medical history  Children with the presence of caries of ICDAS code 3, 4, 5, or 6 on other primary teeth. 2. Children who had received professional fluoride application in the past 6 months. 3. Children with serious systemic disease or taking long term medication. 4. Children who are uncooperative or refuse the treatment. 5. Second primary molars that are (i) with caries in dentin indicated by ICDAS code 4, 5 or 6; (ii) partially erupted; (iii) with fillings and/or sealants; and (iv) hypoplastic or hypomineralized
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Hypophosphatemic Rickets hypophosphatemic rickets patients children from 2 yars-old to 18 years old and adults patients with HR followed in the center of calcium and phosphorus metabolism rare diseases in Lyon- Patients and parent / holder of parental authority who have been informed of the study and do not object to participate  Patient being treated with oral corticosteroid or having received more than 3 months of corticosteroid treatment before surgery Patients under tutorship or curatorship Pregnant and / or breastfeeding woman Patient deprived of liberty Controls patients children from 2 years-old to 18 years old and adults patients with normal renal function (Schwartz glomerular filtration rate (GFR) >90 ml/min/1.73m²) Patients and parent / holder of parental authority who have been informed of the study and do not object to participate Patient being treated with oral corticosteroid or having received more than 3 months of corticosteroid treatment before surgery Patients under tutorship or curatorship Pregnant and / or breastfeeding woman
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Haemophilia Individuals older than 18 years diagnosed with hemophilia A or B having at least one joint with hemophilic arthropathy without cognitive problems speaking turkish  Individuals with another congenital coagulopathy such as Von Willebrand Syndrome unable to walk due to hemophilic arthropathy developing inhibition against factor VIII-IX
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Spinal Cord Injuries SCI at any level, America Spinal injury Association (ASIA) Impairment Scale = A-C Primarily wheelchair-user Age between 18 and 65 years old Two cohorts will be recruited: 1. chronic injury greater than 4 yr and 2. newly injured, less than 4 years The investigators will target Vit D blood level to be 20 ng/ml or higher and suggest that any potential participants with Vit D greater than 10 but below 20 receive a clinical protocol to achieve 20 ng/ml  Presence of hyper/hypo-parathyroidism, renal insufficiency (GFR<60ml/min), currently taking hormone replacement therapy, severe vitamin D deficiency (<10 ng/ml), thyroid disease, active cancer diagnosis, currently using bisphosphonate or parathyroid hormone therapy, diagnosed fracture less than 3 months ago, current pressure sore stage III or IV, New York Heart Association (NYHA) functional classification of stage II-IV, inflammatory bowel disease, cirrhosis of the liver, consuming more than 3 dried plums/day as their regular diet Vitamin D blood level below 10 ng/ml